FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386757056> ?p ?o ?g. }

• W4386757056 abstract "Streptococcus pneumoniae (pneumococcus) is a leading vaccine-preventable cause of childhood invasive disease. Nigeria has the second highest pneumococcal disease burden globally, with an estimated ~49 000 child deaths caused by pneumococcal infections each year. Ten-valent pneumococcal conjugate vaccine (GSK; PCV10) was introduced in December 2014 in a phased approach. However, few studies have characterized the disease-causing pneumococci from Nigeria. This study assessed the prevalence of serotypes, antibiotic susceptibility and genomic lineages using whole genome sequencing and identified lineages that could potentially escape PCV10 (GSK). We also investigated the potential differences in pneumococcal lineage features between children with and without sickle cell disease. A collection of 192 disease-causing pneumococcal isolates was obtained from Kano (n=189) and Abuja (n=3) states, Nigeria, between 1 January 2014 and 31 May 2018. The majority (99 %, 190/192) of specimens were recovered from children aged 5 years or under. Among them, 37 children had confirmed or traits of sickle cell disease. Our findings identified 25 serotypes expressed by 43 Global Pneumococcal Sequence Clusters (GPSCs) and 85 sequence types (STs). The most common serotypes were 14 (18 %, n=35), 6B (16 %, n=31), 1 (9 %, n=17), 5 (9 %, n=17) and 6A (9 %, n=17); all except serotype 6A are included in PCV10 (GSK). PCV10 (SII; PNEUMOSIL) and PCV13 formulations include serotypes 6A and 19A which would increase the overall coverage from 67 % by PCV10 (GSK) to 78 and 82 %, respectively. The pneumococcal lineages were a mix of globally spreading and unique local lineages. Following the use of PCV10 (GSK), GPSC5 expressing serotype 6A, GPSC10 (19A), GPSC26 (12F and 46) and GPSC627 (9L) are non-vaccine type lineages that could persist and potentially expand under vaccine-selective pressure. Approximately half (52 %, 99/192) of the pneumococcal isolates were resistant to the first-line antibiotic penicillin and 44 % (85/192) were multidrug-resistant. Erythromycin resistance was very low (2 %, 3/192). There was no significant difference in clinical manifestation, serotype prevalence or antibiotic resistance between children with and without traits of or confirmed sickle cell disease. In summary, our findings show that a high percentage of the pneumococcal disease were caused by the serotypes that are covered by currently available vaccines. Given the low prevalence of resistance, macrolide antibiotics, such as erythromycin, should be considered as an option to treat pneumococcal disease in Nigeria. However, appropriate use of macrolide antibiotics should be vigilantly monitored to prevent the potential increase in macrolide resistance." @default.
• W4386757056 created "2023-09-16" @default.
• W4386757056 creator A5002395866 @default.
• W4386757056 creator A5006015572 @default.
• W4386757056 creator A5007609770 @default.
• W4386757056 creator A5011166062 @default.
• W4386757056 creator A5022302563 @default.
• W4386757056 creator A5031763725 @default.
• W4386757056 creator A5032214552 @default.
• W4386757056 creator A5043907861 @default.
• W4386757056 creator A5049076258 @default.
• W4386757056 creator A5072851650 @default.
• W4386757056 creator A5073330626 @default.
• W4386757056 creator A5076002328 @default.
• W4386757056 creator A5077269965 @default.
• W4386757056 creator A5077742706 @default.
• W4386757056 creator A5079452871 @default.
• W4386757056 creator A5089106120 @default.
• W4386757056 creator A5090042341 @default.
• W4386757056 date "2023-09-15" @default.
• W4386757056 modified "2023-10-15" @default.
• W4386757056 title "Molecular characterization of Streptococcus pneumoniae causing disease among children in Nigeria during the introduction of PCV10 (GSK)" @default.
• W4386757056 cites W1456171542 @default.
• W4386757056 cites W1806362317 @default.
• W4386757056 cites W1935769679 @default.
• W4386757056 cites W1951816138 @default.
• W4386757056 cites W1963985157 @default.
• W4386757056 cites W2008526009 @default.
• W4386757056 cites W2023964275 @default.
• W4386757056 cites W2031611770 @default.
• W4386757056 cites W2037637239 @default.
• W4386757056 cites W2048546316 @default.
• W4386757056 cites W2070799239 @default.
• W4386757056 cites W2103522837 @default.
• W4386757056 cites W2115657655 @default.
• W4386757056 cites W2283730606 @default.
• W4386757056 cites W2432197333 @default.
• W4386757056 cites W2515546166 @default.
• W4386757056 cites W2559822590 @default.
• W4386757056 cites W2749092259 @default.
• W4386757056 cites W2775739564 @default.
• W4386757056 cites W2784744055 @default.
• W4386757056 cites W2808668519 @default.
• W4386757056 cites W2810449130 @default.
• W4386757056 cites W2889824384 @default.
• W4386757056 cites W2921370113 @default.
• W4386757056 cites W2937635380 @default.
• W4386757056 cites W2949236085 @default.
• W4386757056 cites W2950614621 @default.
• W4386757056 cites W2952194126 @default.
• W4386757056 cites W2952568525 @default.
• W4386757056 cites W2971837699 @default.
• W4386757056 cites W4299627282 @default.
• W4386757056 doi "https://doi.org/10.1099/mgen.0.001094" @default.
• W4386757056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37712828" @default.
• W4386757056 hasPublicationYear "2023" @default.
• W4386757056 type Work @default.
• W4386757056 citedByCount "0" @default.
• W4386757056 crossrefType "journal-article" @default.
• W4386757056 hasAuthorship W4386757056A5002395866 @default.
• W4386757056 hasAuthorship W4386757056A5006015572 @default.
• W4386757056 hasAuthorship W4386757056A5007609770 @default.
• W4386757056 hasAuthorship W4386757056A5011166062 @default.
• W4386757056 hasAuthorship W4386757056A5022302563 @default.
• W4386757056 hasAuthorship W4386757056A5031763725 @default.
• W4386757056 hasAuthorship W4386757056A5032214552 @default.
• W4386757056 hasAuthorship W4386757056A5043907861 @default.
• W4386757056 hasAuthorship W4386757056A5049076258 @default.
• W4386757056 hasAuthorship W4386757056A5072851650 @default.
• W4386757056 hasAuthorship W4386757056A5073330626 @default.
• W4386757056 hasAuthorship W4386757056A5076002328 @default.
• W4386757056 hasAuthorship W4386757056A5077269965 @default.
• W4386757056 hasAuthorship W4386757056A5077742706 @default.
• W4386757056 hasAuthorship W4386757056A5079452871 @default.
• W4386757056 hasAuthorship W4386757056A5089106120 @default.
• W4386757056 hasAuthorship W4386757056A5090042341 @default.
• W4386757056 hasBestOaLocation W43867570561 @default.
• W4386757056 hasConcept C10389963 @default.
• W4386757056 hasConcept C104317684 @default.
• W4386757056 hasConcept C126322002 @default.
• W4386757056 hasConcept C159047783 @default.
• W4386757056 hasConcept C2776152631 @default.
• W4386757056 hasConcept C2776817793 @default.
• W4386757056 hasConcept C2778866548 @default.
• W4386757056 hasConcept C2779134260 @default.
• W4386757056 hasConcept C2781253189 @default.
• W4386757056 hasConcept C3020803494 @default.
• W4386757056 hasConcept C501593827 @default.
• W4386757056 hasConcept C54355233 @default.
• W4386757056 hasConcept C71924100 @default.
• W4386757056 hasConcept C86803240 @default.
• W4386757056 hasConcept C89423630 @default.
• W4386757056 hasConceptScore W4386757056C10389963 @default.
• W4386757056 hasConceptScore W4386757056C104317684 @default.
• W4386757056 hasConceptScore W4386757056C126322002 @default.
• W4386757056 hasConceptScore W4386757056C159047783 @default.
• W4386757056 hasConceptScore W4386757056C2776152631 @default.
• W4386757056 hasConceptScore W4386757056C2776817793 @default.
• W4386757056 hasConceptScore W4386757056C2778866548 @default.
• W4386757056 hasConceptScore W4386757056C2779134260 @default.

• next